Summit Therapeutics Inc.
SMMT
Kedudukan dalam Saham
#1681
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$16.11
Modal Pasaran
$12.85B
Perubahan (1 hari)
0.09%
Perubahan (1 tahun)
-14.06%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Hasil untuk Summit Therapeutics Inc. (SMMT)
Hasil pada Jun 2026 TTM: 0.00
Menurut laporan kewangan terkini daripada Summit Therapeutics Inc., hasil semasa syarikat (TTM) ialah 0.00. Pada tahun 2023, syarikat memperoleh hasil sebanyak 0.00 penurunan berbanding hasil pada tahun 2022 iaitu $704.30K. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Summit Therapeutics Inc. dari 2004 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $704.30K | -61.07% |
| 2021 | $1.81M | 110.35% |
| 2020 | $860.00K | 5.99% |
| 2019 | $811.40K | -96.73% |
| 2018 | $24.84M | 585.22% |
| 2017 | $3.63M | 98.76% |
| 2016 | $1.82M | -46.59% |
| 2015 | $3.42M | -8.39% |
| 2014 | $3.73M | -17.91% |
| 2013 | $4.54M | 3.93% |
| 2012 | $4.37M | 126.58% |
| 2011 | $1.93M | 297.91% |
| 2010 | $484.72K | 26.56% |
| 2009 | $383.00K | -96.80% |
| 2008 | $11.98M | 201.54% |
| 2007 | $3.97M | 135.85% |
| 2006 | $1.68M | 320.18% |
| 2005 | $400.93K | 11,995.06% |
| 2004 | $3.31K | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
